Johnson & Johnson Shares Rise 1.19% in Two Days as CAR T-cell Therapy Shows Promising Results Trading Volume Ranks 73rd

Johnson & Johnson (JNJ) shares rose 0.28% on June 13, 2025, marking the second consecutive day of gains, with a total increase of 1.19% over the past two days. The trading volume reached 10.35 billion, ranking 73rd in the day's market activity.

Johnson & Johnson's dual-targeting CAR T-cell therapy, JNJ-90014496, has shown promising results in a Phase 1b study. The therapy, designed to target both CD19 and CD20 proteins on cancer cells, demonstrated complete response rates of 75-80% among patients with relapsed or refractory B-cell malignancies. This novel approach highlights the potential of dual-targeting CAR T-cell therapies in improving treatment outcomes for cancer patients.

Additionally, Johnson & Johnson announced new Phase 1b data for bleximenib, showing encouraging antileukemic activity and a promising safety profile. This data further underscores the company's commitment to developing innovative therapies for cancer treatment.